{"article_title": "The FDA's Priority List For 2016", "article_keywords": ["cder", "schweitzer", "therapeutics", "drugs", "list", "subagency", "drug", "priority", "summit", "york", "2016", "woodcock", "fdas", "view"], "article_url": "http://www.law360.com/articles/751420/the-fda-s-priority-list-for-2016", "article_text": "The FDA's Priority List For 2016\n\nLaw360, New York (January 29, 2016, 11:03 AM ET) -- Erica Cribbs\n\n\n\nGretchen E. Harper\n\n\n\nApril E. Schweitzer The Food and Drug Administration\u2019s Center for Drug Evaluation and Research (CDER) director, Janet Woodcock, outlined the agency\u2019s priorities for the coming year at the FDA/Centers for Medicare and Medicaid Summit for Biopharma Executives on Dec. 14-15, 2015.[1] The CDER, a subagency within the larger purview of the FDA, regulates over-the-counter and prescription drugs, including biological therapeutics and generic drugs, thereby ensuring that safe and effective drugs are available to improve the health of the U.S. population....\n\nTo view the full article, register now.", "article_metadata": {"description": "The U.S. Food and Drug Administration has big plans for 2016, including negotiating the sixth reauthorization for the Prescription Drug User Fee Act, continuing to implement its biosimilars program, integrating the Sentinel Network and potentially developing labeling rules specific to different types of drugs, say attorneys at Nixon Peabody LLP.", "apple-itunes-app": "app-id=934560389, app-argument=law360://www.law360.com/articles/751420/the-fda-s-priority-list-for-2016", "csrf-token": "/EZJKhSwYrS5nnH56Y3x4wiDWkT0iEqdg5/bJBh9mlSushKeEg/TYhH8QZB+vj5F01iYbY43jnFVUpP2UdfGFg==", "csrf-param": "authenticity_token", "og": {"url": "http://www.law360.com/articles/751420/the-fda-s-priority-list-for-2016", "image": "https://www.law360.com/images/360.png", "type": "website", "title": "The FDA's Priority List For 2016 - Law360"}, "viewport": "width=device-width, initial-scale=1.0"}, "article_summary": "The FDA's Priority List For 2016Law360, New York (January 29, 2016, 11:03 AM ET) -- Erica CribbsGretchen E. HarperApril E. Schweitzer The Food and Drug Administration\u2019s Center for Drug Evaluation and Research (CDER) director, Janet Woodcock, outlined the agency\u2019s priorities for the coming year at the FDA/Centers for Medicare and Medicaid Summit for Biopharma Executives on Dec. 14-15, 2015.\n[1] The CDER, a subagency within the larger purview of the FDA, regulates over-the-counter and prescription drugs, including biological therapeutics and generic drugs, thereby ensuring that safe and effective drugs are available to improve the health of the U.S. population....To view the full article, register now."}